Kaye et al. also reported a case of ameloblastoma stage IV (local recurrence, cervical metastatic lymph nodes, and pulmonary nodules) that responded well to oral bitherapy with a BRAF inhibitor (dabrafenib) and a mitogen-activated extracellular signal-regulated kinase inhibitor (trametinib) [8]. This evidence concerns the gene BRAF and ameloblastoma.